| Literature DB >> 22226569 |
Anne Ploquin1, David Olmos, Charles Ferté, Philippe A Cassier, Andrew Kramar, Alain Duhamel, Nicolas Penel.
Abstract
Life-expectancy superior to 3 months is a key-eligibility criterion for contemporary oncology phase 1 trials. Nevertheless, there is no reliable and consensual guidance for estimating this criterion. We have conducted a systematic review of published studies investigating the risk factor for 90-day mortality and the inherent generated scores. Nine studies have been published on this topic. Only two of these prognostic models have been validated on an independent dataset. Most of the models are based on a very subjective and investigator-dependent parameter: the performance status. The predictive performance of these prognostic models is poorly evaluated.Entities:
Mesh：
Year: 2012 PMID： 22226569 DOI： 10.1016/j.critrevonc.2011.11.008
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312